218 related articles for article (PubMed ID: 23053255)
1. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
2. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
Nygren P; Hande K; Petty KJ; Fedgchin M; van Dyck K; Majumdar A; Panebianco D; de Smet M; Ahmed T; Murphy MG; Gottesdiener KM; Cocquyt V; van Belle S
Cancer Chemother Pharmacol; 2005 Jun; 55(6):609-16. PubMed ID: 15723220
[TBL] [Abstract][Full Text] [Related]
3. Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.
Fabre C; Gobbi M; Ezzili C; Zoubir M; Sablin MP; Small K; Im E; Shinwari N; Zhang D; Zhou H; Le Tourneau C
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1057-64. PubMed ID: 25217392
[TBL] [Abstract][Full Text] [Related]
4. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
5. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.
Nemunaitis JJ; Small KA; Kirschmeier P; Zhang D; Zhu Y; Jou YM; Statkevich P; Yao SL; Bannerji R
J Transl Med; 2013 Oct; 11():259. PubMed ID: 24131779
[TBL] [Abstract][Full Text] [Related]
6. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Hsyu PH; Pignataro DS; Matschke K
Eur J Clin Pharmacol; 2017 Jan; 73(1):49-56. PubMed ID: 27718000
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
[TBL] [Abstract][Full Text] [Related]
9. Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Loos WJ; de Wit R; Freedman SJ; Van Dyck K; Gambale JJ; Li S; Murphy GM; van Noort C; de Bruijn P; Verweij J
Cancer Chemother Pharmacol; 2007 Feb; 59(3):407-12. PubMed ID: 17051369
[TBL] [Abstract][Full Text] [Related]
10. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone.
McCrea JB; Majumdar AK; Goldberg MR; Iwamoto M; Gargano C; Panebianco DL; Hesney M; Lines CR; Petty KJ; Deutsch PJ; Murphy MG; Gottesdiener KM; Goldwater DR; Blum RA
Clin Pharmacol Ther; 2003 Jul; 74(1):17-24. PubMed ID: 12844131
[TBL] [Abstract][Full Text] [Related]
11. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.
Xiong J; Zhao G; Yang S; Chen J
Adv Ther; 2019 Feb; 36(2):355-364. PubMed ID: 30607545
[TBL] [Abstract][Full Text] [Related]
13. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Gore L; Chawla S; Petrilli A; Hemenway M; Schissel D; Chua V; Carides AD; Taylor A; Devandry S; Valentine J; Evans JK; Oxenius B;
Pediatr Blood Cancer; 2009 Feb; 52(2):242-7. PubMed ID: 18985740
[TBL] [Abstract][Full Text] [Related]
14. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
16. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America.
Poli-Bigelli S; Rodrigues-Pereira J; Carides AD; Julie Ma G; Eldridge K; Hipple A; Evans JK; Horgan KJ; Lawson F;
Cancer; 2003 Jun; 97(12):3090-8. PubMed ID: 12784346
[TBL] [Abstract][Full Text] [Related]
17. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
19. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Suzuki S; Karayama M; Inui N; Kuroishi S; Fujisawa T; Enomoto N; Nakamura Y; Yokomura K; Toyoshima M; Imokawa S; Asada K; Masuda M; Yamada T; Watanabe H; Hayakawa H; Suda T
Med Oncol; 2016 Jul; 33(7):65. PubMed ID: 27235141
[TBL] [Abstract][Full Text] [Related]
20. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Blum RA; Majumdar A; McCrea J; Busillo J; Orlowski LH; Panebianco D; Hesney M; Petty KJ; Goldberg MR; Murphy MG; Gottesdiener KM; Hustad CM; Lates C; Kraft WK; Van Buren S; Waldman SA; Greenberg HE
Clin Ther; 2003 May; 25(5):1407-19. PubMed ID: 12867217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
